Meral Beksac
@mbeksac56
Professor of Hematology, Ankara Liv Hosp, Istinye Univ, TurkHemSociety MM committee chair( MmGTr), EMN senior board , EBMT PCD vice chair, BMSG vice president
June 2022 ASCO education session: When monoclonal gammopathy is not myeloma. Open access review on SMM, AL Amyloidosis and Waldenström
Amazing results. Given the failure of antifibril drugs this is a new hope
#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: pubmed.ncbi.nlm.nih.gov/40712156/. #mmsm
Quadruplets are the new standard of induction in myeloma regardless of transplant eligibility
🚨 NEWS 🚨 @EU_Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:…
🔴 Güzel haberi paylaşayım! DÜNYA SANAT VE BİLİM AKADEMİSİNDE (@_WAAS_) MÜTEVELLİ HEYETİNE seçilen ülkemizden ilk bilim insanı ve dünyadan ilk beyin cerrahı oldum. Albert Einstein ve Bertrand Russell ve Robert Oppenheimer’ın kurucu fikir ve katkılarıyla, Birleşmiş Milletlere…
Dünya Sanat ve Bilim Akademisine (WAAS) seçildim Einstein ve Russell’ın fikir babalığını yaptığı bu 62 yıllık akademiye ülkemizden kabul alan 8. bilim insanı ilk beyin cerrahı oldum Bu sevincimden daha fazlası ancak (ümit ederim ki) öğrencilerimden birinin Nobel alması olabilir
Following the very successful experience in DREAMM-8 We are fortunate to have an early access program in Turkey with Belamaf
Belantamab Mafodotin Combos Receive EU, Canadian Approval for R/R Myeloma #MMSM #MultipleMyeloma onclive.com/view/belantama…
Proud to share our review on transthyretin amyloid cardiomyopathy! doi.org/10.1007/s40119… We break down the current treatments, what’s in the pipeline, and what’s next. @UreyTony @UCSDCardiology
“BİLİM İNSANI ve HEKİM” OLMAK İSTEYEN TIP İSTEKLİLERİNE👇 (40 tıp öğrencisine böylesi bir bursu verebilmek kolay değil bu duyurunun yayılmasına yardımcı olmanızı rica ederim🙂) İstinye Tıp 40 öğrenci ile sınırlanmış burslu bir BİLİM SINIFI seçiyor. Tam eğitim ve yurt bursunun…
The paper of the day: a landmark publication that is bound to serve as a reference for years to come! @NatRevClinOncol @thanosdimop @COMyCongress @TheIACH @mbeksac56
Yeni bir antiBCMA Miyelom imunoterapi ilacı daha onay aldı. Yakında hem yeni tanı hem de nüks hastalarda klinik çalışmaları ülkemize geliyor.
FDA grants accelerated approval to a treatment for relapsed or refractory multiple myeloma. fda.gov/drugs/resource…
‼️𝘖𝘶𝘳 𝘭𝘢𝘵𝘦𝘴𝘵 @TheIACH 𝘱𝘰𝘴𝘵 𝘈𝘚𝘊𝘖 𝘌𝘏𝘈 𝘊𝘖𝘔𝘺 𝘳𝘰𝘶𝘯𝘥𝘵𝘢𝘣𝘭𝘦 𝘥𝘪𝘴𝘤𝘶𝘴𝘴𝘪𝘰𝘯 𝗗𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝗟𝗮𝘁𝗲𝘀𝘁 𝗠𝘆𝗲𝗹𝗼𝗺𝗮 𝗗𝗮𝘁𝗮 𝗮𝗻𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 📽️𝘕𝘰𝘸 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘰𝘯…
New issue of the Balkan Medical Journal (SCI-E, Q1) (Vol. 42, Issue 4) is now available. balkanmedicaljournal.org/content.php?id… #ProstatCancer #AntimyelomaTCell #LatticeRadiotherapy #PleuralNeedleBiopsy #TauPatology #TryglycerideGlucoseIndex #Atherosclerosis #p90RSKNrf2Pathway #BuriedBumperSy
Thank you to our colleagues at the Moroccan Society of Hematology for co-hosting our educational workshop! We had a great time learning with you. We hope to see you again soon.
Once more congratulations @NoopurRajeMD for a very successful program lots of case discussions and inspiring educational lectures
@Myeloma_Society educational workshop in Marrakech with @NikhilMunshiMD @SagarLonialMD @myelomaMD @mbeksac56 @szusmani ..excellent talks and great cases.. stay tuned for accessing the web content.
Thanks for posting Mike for posting and Linda for writing it’s critical to take this guidance seriously and to perform these test with good quality control to ensure patients receive optimum therapy - we should now move on to a molecular based approach
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group [Jun 18, 2025] Lu et al. @lbaughn @BloodCancerJnl nature.com/articles/s4140… #mmsm #hemepath…
Congrats for achieving such a great success @TheEBMT @TheEBMT_CTIWP
@lucila_kerbauy presenting her group’s experience with locally manufactured CAR T cells in São Paulo
𝗪𝗲 𝗮𝗿𝗲 𝗟𝗜𝗩𝗘 @TheIACH 𝘱𝘰𝘴𝘵 𝘈𝘚𝘊𝘖 𝘌𝘏𝘈 𝘊𝘖𝘔𝘺 𝘳𝘰𝘶𝘯𝘥𝘵𝘢𝘣𝘭𝘦 𝘥𝘪𝘴𝘤𝘶𝘴𝘴𝘪𝘰𝘯 𝗗𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝗟𝗮𝘁𝗲𝘀𝘁 𝗠𝘆𝗲𝗹𝗼𝗺𝗮 𝗗𝗮𝘁𝗮 𝗮𝗻𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 𝗙𝗥𝗘𝗘 𝗥𝗘𝗚𝗜𝗦𝗧𝗥𝗔𝗧𝗜𝗢𝗡 ⬇️⬇️…
Honoured to take part in the program. What a great faculty and opportunity for North Africa @NoopurRajeMD @szusmani @SLentzsch @Mohty_EBMT online free for @Myeloma_Society members
There is still time to register for the IMS Educational Workshop in #Marrakech, June 27-28. We hope to see you there! ow.ly/iLsc50VcU2y
Quadruplets offer a projected median PFS of 17 YEARS: After PERSEUS DaraVRd now GMMG-HD7 IsaVRd is coming
🚨NEWS 🚨 The CHMP recommends EC approval of isatuximab in combination with VRd for the treatment of transplant-eligible patients with newly diagnosed #MultipleMyeloma based on results from the phase III GMMG-HD7 trial. Read more: loom.ly/F9BClxs #myeloma #MedEd…
Elran + DR for transplant ineligible myeloma patients. Impressive response rates with Q4W dosing of Elran. Looking forward to the treatment deescalation strategies in phase 3 #EHA2025
#EHA2025 #EHA25 Wonderful job 👏 👏 👏 oral presentation at @EHA_Hematology by our own @MusaYilmazMD @MDAndersonNews on DEC/VEN/QUIZ combination for patients w/ #FLT3ITD AML || @sanamloghavi @Daver_Leukemia
Late breaking abstract 📢 Tec + Tal showing high response in EMD with strict central response assessments. Good to see dual antigen targeting making a difference in this high risk group. #mmsm #EHA2025